Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.62 |
| ▸ | BRAF | P15056 | 14/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | PLK4 | O00444 | 1/20 | 0.52 |
| ▸ | ACOX3 | O15254 | 1/20 | 0.52 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.52 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | ERN1 | O75460 | 1/20 | 0.52 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.52 |
| ▸ | STK10 | O94804 | 1/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | RAF1 | P04049 | 1/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | FYN | P06241 | 1/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | FES | P07332 | 1/20 | 0.52 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1410350 | 0.93 | MAPK14 (0.60) | MAPK14BRAFPLK4ACOX3MAP3K7 | |
| SCHEMBL1410533 | 0.88 | MAPK14 (0.71) | MAPK14BRAFKCNH2PLK4ACOX3 | |
| SCHEMBL1128969 | 0.87 | MAPK14 (0.69) | MAPK14BRAFKCNH2PLK4ACOX3 | |
| SCHEMBL1410345 | 0.86 | MAPK14 (0.66) | MAPK14BRAFKCNH2PLK4ACOX3 | |
| SCHEMBL1410386 | 0.83 | MAPK13 (0.61) | MAPK14BRAFMAP3K7ABL1RAF1 | |
| SCHEMBL1410565 | 0.83 | MAPK14 (0.62) | MAPK14BRAFKCNH2PLK4ACOX3 | |
| SCHEMBL1410647 | 0.82 | MAPK14 (0.69) | MAPK14BRAFPLK4ACOX3MAP3K7 | |
| SCHEMBL1410376 | 0.82 | MAPK14 (0.63) | MAPK14BRAFKCNH2PLK4ACOX3 | |
| SCHEMBL1410551 | 0.82 | MAPK14 (0.70) | MAPK14BRAFKCNH2PLK4ACOX3 | |
| SCHEMBL1410738 | 0.81 | MAPK14 (0.68) | MAPK14BRAFKCNH2PLK4ACOX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751139-B1 | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2011-07-27 | — | — | EP | claimed |
| EP-2295427-A1 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | Bayer HealthCare, LLC (US) | 2011-03-16 | — | — | EP | claimed |
| EP-2295426-A1 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | Bayer HealthCare, LLC (US) | 2011-03-16 | — | — | EP | claimed |
| US-7838524-B2 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | BAYER HEALTHCARE LLC (US) | 2010-11-23 | — | — | US | claimed |
| US-20080214545-A1 | Substituted Pyrazolyl Urea Derivatives Useful in the Treatment of Cancer | BAYER HEALTHCARE LLC | 2008-09-04 | — | — | US | claimed |
| US-8207166-B2 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | BAYER HEALTHCARE LLC (US) | 2012-06-26 | — | — | US | disclosed |
| EP-1751139-B1 | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20110136809-A1 | Substituted Pyrazolyl Urea Derivatives Useful In The Treatment Of Cancer | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2295427-A1 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | Bayer HealthCare, LLC (US) | 2011-03-16 | — | — | EP | disclosed |
| EP-2295426-A1 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | Bayer HealthCare, LLC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7838524-B2 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | BAYER HEALTHCARE LLC (US) | 2010-11-23 | — | — | US | disclosed |
| US-20080214545-A1 | Substituted Pyrazolyl Urea Derivatives Useful in the Treatment of Cancer | BAYER HEALTHCARE LLC | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214545-A1 | Substituted Pyrazolyl Urea Derivatives Useful in the Treatment of Cancer | UMPS, SLC14A1, TP53 | MAPK14 2675/4885BRAF 159/4885KCNH2 3590/4885 |
| US-20110136809-A1 | Substituted Pyrazolyl Urea Derivatives Useful In The Treatment Of Cancer | UMPS, SLC14A1, TP53 | MAPK14 2675/4885BRAF 159/4885KCNH2 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.